Business
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
LONDON AND HONG KONG, Mar 4, 2023 - (ACN Newswire) - - Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to
About this update from Prenetics Global Limited
[{"type":"text","content":"LONDON AND HONG KONG, Mar 4, 2023 - (ACN Newswire) - - Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB') to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics' diagnostic cancer genomics platform.Prenetics has been at the forefront of genomic and diagnostic testing, providing a wide range of genetic testing services to individuals and healthcare professionals around the world. The SAB includes a diverse group of highly respected experts in oncology and genomics, each with unique expertise and backgrounds in the field of precision oncology. Members of the board include Prof. Tony Mok, Prof. Pasi Janne, Prof. Pan-Chyr Yang, Dr. Hua-Chien Chen, Dr. Frank Ong, and Dr. Lawrence Tzang.\"We are honoured to have these accomplished scientific thought-leaders join Prenetics' SAB,\" said Danny Yeung, CEO and Co-Founder of Prenetics. \"Their insights and experience will be an invaluable asset to fuel our innovative solutions in the field of precision oncology. We are particularly excited in the area of early detection for cancer and will share more details in the coming months.\"\"We are thrilled to have Prof. Mok chair our SAB,\" Mr. Yeung continued, \"Prof. Mok's passion for innovation make him a great fit for Prenetics and look forward to working together to transform the way cancer is identified and treated. Prof. Mok's research has already guided the development of breakthroughs for lung cancer treatment and he has been recognized globally for his impact on the field of precision oncology.\"Prof. Mok added \"I am delighted to be joining Prenetics and to have the opportunity to work with such a dynamic and innovative team. Precision oncology is a rapidly evolving field, and I believe that Prenetics is well-positioned to make a significant impact in this area. I look forward to contributing my expertise to this important work.\"Prenetics' SAB appointees include:Prof. Tony S. K. Mok Prof. Mok will lead the SAB and currently serves as Chairman of the Department of Clinical Oncology of Chinese University of Hong Kong, is a non-executive director of AstraZeneca plc (LON:AZN), and an independent director of HUTCHMED (China) Limited (Nasd...